Potential of Bifidobacteriumlactis IDCC 4301 isolated from breast milk‐fed infant feces as a probiotic and functional ingredient

Abstract

Probiotics provide important health benefits to the host by improving intestinal microbial balance and have been widely consumed as dietary supplements. In this study, we investigated whether Bifidobacterium lactis IDCC 4301 (BL), isolated from feces of breast milk‐fed infants, is safe to consume. Based on the guidelines established by the European Food Safety Authority (EFSA), safety tests such as antibiotic susceptibility, hemolysis, toxic compound formation (i.e., biogenic amine and d‐lactate), single‐dose acute oral toxicity, and extracellular enzymatic activities were performed. In addition, toxigenic genes, antibiotic resistance genes, and mobile genetic elements were investigated by analyzing the genome sequence of BL. BL was susceptible to eight antibiotics except for vancomycin and the absence of transferable resistance in the genome of this strain implied that vancomycin resistance is likely to be intrinsic. With regard to phenotypic characteristics, there was no concern of toxicity of this strain. Furthermore, BL utilized various carbohydrates and their conjugates through the activity of various endogenous carbohydrate‐utilizing enzymes. Interestingly, the supernatant of the BL showed strong antipathogenic activity against various infectious pathogens. Therefore, we suggest that BL should be a safe probiotic and can be used as a functional ingredient in the food, cosmetic, and pharmaceutical industries.

Gut microbial change after administration of Lacticaseibacillus paracasei AO356 is associated with anti-obesity in a mouse model

“…Particularly, it could be severe problems in infants an in patients with short bowel syndrome. Thus, the FAO/WHO requires information about D-lactate production to assess the safety of probiotics, and recommended that the product label should specify the information about strains that produce D-lacate ( 76 , 77 ). In this study, we confirmed that L. paracasei AO356 mainly produced L-lactate and rarely produced D-lactate, which is similar to L. rhamnosus GG , commercial probiotics.…”

Isolation, Characterization, and Safety Evaluation of the Novel Probiotic Strain Lacticaseibacillus paracasei IDCC 3401 via Genomic and Phenotypic Approaches

“…To examine the antipathogenic effects of L. paracasei IDCC 3401, a previously described method [ 28 ] was used with a minor modification. The supernatants of L. paracasei IDCC 3401 were harvested via centrifugation at 8000 rpm and 4 °C for 30 min, followed by filtering through a 0.20 µm syringe filter to remove residual bacteria.…”

Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity

“…Their decline has been linked to an elevated risk of immune–metabolic conditions such as obesity, T2DM, and metabolic syndrome [ 89 , 90 , 91 ]. The two most frequent genera are Lactobacillus and Bifidobacterium [ 92 ]. Despite the absence of approval from medical regulatory authorities like the European Food Safety Authority and the US Food and Drug Administration for any probiotic formulation as a therapeutic agent [ 93 , 94 , 95 ], in compliance with the guidelines established by the Ministry of Food and Drug Safety (MFDS) for healthful functional foods, South Korea uses 19 probiotic species as functional ingredients.…”